title: Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
abstract: The objective of this study was to examine the in vitro combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells FTC133 using a MTT cytotoxicity assay, and to test whether the mechanism involves induction of apoptosis. The present results demonstrated that curcumin at 15-25 μM dose-dependently suppressed the proliferation of FTC133. Combined treatment (curcumin (25 μM) and sorafenib (2 μM)) resulted in a reduction in cell colony formation and significantly decreased the invasion and migration of FTC133 cells compared with that treated with individual drugs. Western blot showed that the levels of p-ERK and p-Akt proteins were significantly reduced (p < 0.01) in the medicine-treated FTC133 cells. The curcumin was found to dose-dependently inhibit the apoptosis of FTC133 cells possibly via PI3K/Akt and ERK pathways. There is a synergetic antitumour effect between curcumin and sorafenib.
authors: a Department of Thyroid Surgery , The Second Affiliated Hospital to Nanchang University , Nanchang , China.
authors: Junjia
authors: J
authors: Zhang
authors: a Department of Thyroid Surgery , The Second Affiliated Hospital to Nanchang University , Nanchang , China.
authors: Jichun
authors: J
authors: Yu
authors: a Department of Thyroid Surgery , The Second Affiliated Hospital to Nanchang University , Nanchang , China.
authors: Rong
authors: R
authors: Xie
authors: a Department of Thyroid Surgery , The Second Affiliated Hospital to Nanchang University , Nanchang , China.
authors: Wanzhi
authors: W
authors: Chen
authors: a Department of Thyroid Surgery , The Second Affiliated Hospital to Nanchang University , Nanchang , China.
authors: Yunxia
authors: Y
authors: Lv
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D003474:Curcumin
keywords: Curcumin; PI3K/Akt and ERK pathways; antitumour; sorafenib